Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis.

Feng B, Verstovsek S, Jorgensen JL, Lin P.

Am J Clin Pathol. 2010 Feb;133(2):314-20. doi: 10.1309/AJCPNC99DHXIOOTD.

PMID:
20093242
2.

Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis.

Bae E, Park CJ, Cho YU, Seo EJ, Chi HS, Jang S, Lee KH, Lee JH, Lee JH, Suh JJ, Im HJ.

Int J Lab Hematol. 2013 Dec;35(6):629-36. doi: 10.1111/ijlh.12101. Epub 2013 May 22.

PMID:
23693053
3.

Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.

Ouyang J, Zheng W, Shen Q, Goswami M, Jorgensen JL, Medeiros LJ, Wang SA.

Cytometry B Clin Cytom. 2015 Jul-Aug;88(4):236-43. doi: 10.1002/cyto.b.21215. Epub 2014 Dec 30.

4.

[Diagnostic significance of immunophenotyping of bone marrow cells in myelodysplastic syndrome without an increase of marrow blasts].

Xu J, Zhang W, Liu Y, Wan SG, Sun XJ, Zhao H.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Dec;17(6):1477-81. Chinese.

PMID:
20030930
5.

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.

Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17.

PMID:
19616600
6.

[Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].

Li LJ, Fu R, Wang HQ, Yue LZ, Liu H, Wang J, Wang HL, Ruan EB, Qu W, Liang Y, Wang GJ, Wang XM, Liu H, Song J, Wu YH, Xing LM, Guan J, Shao ZH.

Zhonghua Yi Xue Za Zhi. 2010 Mar 16;90(10):672-7. Chinese.

PMID:
20450725
7.

[The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].

Gong XB, Zhang XH, Lu XG, Tang QS, Gao X, Yang J.

Zhonghua Xue Ye Xue Za Zhi. 2012 Jan;33(1):25-30. Chinese.

PMID:
22575188
8.

Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis.

Akiyama T, Matsunaga T, Terui T, Miyanishi K, Tanaka I, Sato T, Kuroda H, Takimoto R, Takayama T, Kato J, Yamauchi N, Kogawa K, Sakamaki S, Hirayama Y, Kohda K, Niitsu Y.

Leukemia. 2005 Sep;19(9):1558-66.

PMID:
16034467
9.

Immunophenotypic features of granulocytes, monocytes, and blasts in myelodysplastic syndromes.

Moon HW, Huh JW, Lee M, Hong KS, Chung WS.

Korean J Lab Med. 2010 Apr;30(2):97-104. doi: 10.3343/kjlm.2010.30.2.97.

10.

[Analysis of clinical features and prognosis of primary myelodysplastic syndromes with myelofibrosis patients].

Su T, Zhang PH, Xu ZF, Chen HS, Qin TJ, Zhang Y, Zhang HL, Fan LW, Pan LJ, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2012 May;33(5):378-82. Chinese.

PMID:
22781796
11.

Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines.

Bock O, Höftmann J, Theophile K, Hussein K, Wiese B, Schlué J, Kreipe H.

Am J Pathol. 2008 Apr;172(4):951-60. doi: 10.2353/ajpath.2008.071030. Epub 2008 Mar 18.

12.

A combination of CD15/CD10, CD64/CD33, CD16/CD13 or CD11b flow cytometric granulocyte panels is sensitive and specific for diagnosis of myelodysplastic syndrome.

Chung JW, Park CJ, Cha CH, Cho YU, Jang S, Chi HS, Seo EJ, Lee JH, Lee JH, Lee KH, Im HJ, Seo JJ.

Ann Clin Lab Sci. 2012 Summer;42(3):271-80.

PMID:
22964615
13.

Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients.

Bellos F, Alpermann T, Gouberman E, Haferlach C, Schnittger S, Haferlach T, Kern W.

Cytometry B Clin Cytom. 2012 Sep;82(5):295-304. doi: 10.1002/cyto.b.21026. Epub 2012 May 17.

14.

Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.

Sangle N, Cook J, Perkins S, Teman CJ, Bahler D, Hickman K, Wilson A, Prchal J, Salama ME.

Appl Immunohistochem Mol Morphol. 2014 Oct;22(9):663-8. doi: 10.1097/PAI.0000000000000000.

15.

Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis.

Tognon R, Gasparotto EP, Neves RP, Nunes NS, Ferreira AF, Palma PV, Kashima S, Covas DT, Santana M, Souto EX, Zanichelli MA, Simões BP, de Souza AM, Castro FA.

J Hematol Oncol. 2012 Feb 2;5:2. doi: 10.1186/1756-8722-5-2.

16.

Immunophenotype of myeloid granulocytes: a pilot study for distinguishing myelodysplastic syndrome and aplastic anemia by flow cytometry.

Huang M, Li J, Zhao G, Sui X, Zhao X, Xu H.

Int J Lab Hematol. 2010 Jun;32(3):275-81. doi: 10.1111/j.1751-553X.2009.01192.x. Epub 2009 Nov 30.

PMID:
19968721
17.

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.

Ha JS, Kim YK, Jung SI, Jung HR, Chung IS.

Ann Lab Med. 2012 Nov;32(6):385-91. doi: 10.3343/alm.2012.32.6.385. Epub 2012 Oct 17.

18.

Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.

Barosi G, Rosti V, Bonetti E, Campanelli R, Carolei A, Catarsi P, Isgrò AM, Lupo L, Massa M, Poletto V, Viarengo G, Villani L, Magrini U.

PLoS One. 2012;7(4):e35631. doi: 10.1371/journal.pone.0035631. Epub 2012 Apr 20.

19.

Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.

Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.

Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.

PMID:
25171702
20.

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.

Helbig G, Wieczorkiewicz A, Woźniczka K, Wiśniewska-Piąty K, Rusek A, Kyrcz-Krzemień S.

Med Oncol. 2012 Dec;29(4):2379-84. doi: 10.1007/s12032-012-0190-3. Epub 2012 Mar 1.

PMID:
22383244

Supplemental Content

Support Center